Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series.
Crit Rev Oncol Hematol
; 140: 80-87, 2019 Aug.
Article
de En
| MEDLINE
| ID: mdl-31133463
ABSTRACT
BACKGROUND:
Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic urothelial cancer after failure of platinum-containing therapy. We performed a systematic review and meta-analysis of real-world data (RWD) to assess utilization, efficacy and safety of VFL.METHODS:
We performed a MEDLINE search for the period of 1/1/2000-31/8/2017. Full-length articles providing post-marketing RWD on VFL in patients failing previous chemotherapy were eligible. Interventional clinical trials were excluded.RESULTS:
Ten studies with 797 patients were identified. According to pooled REs analysis, overall response rate was 19%, most frequent, all-grade toxicities were fatigue (41%), constipation (39%), nausea/vomiting (25%), and most prevalent Grade 3-4 toxicities were neutropenia (13%), anaemia (9%), fatigue (8%). Median OS was comparable to results reported in recent randomized studies.CONCLUSION:
Our findings confirm the efficacy and safety of VFL in an unselected population and support the use of VFL in the changing treatment paradigm of relapsed mUC.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Vinblastine
/
Protocoles de polychimiothérapie antinéoplasique
/
Tumeurs urologiques
Type d'étude:
Clinical_trials
/
Prognostic_studies
/
Systematic_reviews
Limites:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Pays/Région comme sujet:
Europa
Langue:
En
Journal:
Crit Rev Oncol Hematol
Sujet du journal:
HEMATOLOGIA
/
NEOPLASIAS
Année:
2019
Type de document:
Article